多基因风险评分指导的个性化骨质疏松症查:基于人口的研究
Dongxue Wang1, Wen Sun1, Di Liu1
1Faculty of Health Sciences, University of Macau, Taipa, Macau SAR, China.
BMC medicine
|January 14, 2026
概括
使用多基因风险评分 (PRS) 的个性化骨质疏松症查可以比目前的指南早几年识别高风险女性. 这种精确的方法旨在减少骨质疏松性骨折的负担.
科学领域:
- 遗传学和精准医学 遗传学和精准医学
- 骨健康和骨质疏松症研究
- 预防性医疗保健战略 预防性医疗保健策略
背景情况:
- 遗传因素显著影响骨质疏松症的发展和骨折风险.
- 目前的骨质疏松症查指南不包括遗传风险评估.
- 需要基于个体遗传倾向的个性化查协议.
研究的目的:
- 使用多基因风险分数 (PRS) 确定个性化骨质疏松症查年龄.
- 评估PRS在早期发现骨质疏松症方面的潜力.
- 推进骨质疏松症的精确预防策略.
主要方法:
- 来自英国生物银行的223,818名女性的前性队列研究.
- 参与者被分为低,中,高PRS分组.
- 计算了10年累积骨质疏松症风险,风险调整的查年龄和风险推进期 (RAP).
主要成果:
- 在65岁时,一般女性人口的10年骨质疏松症风险为5.95%.
- 高PRS的女性在60岁时达到这一门;低PRS的女性在69岁时达到这一门.
- 高PRS的个体比中等PRS (4.99年早些时候) 发展骨质疏松症.
结论:
- 将PRS整合到骨质疏松症查中可以彻底改变预防.
- 在基因高风险女性中,早期检测是可能的,这比目前的指导方针更早.
- 这种精确的预防方法可以显著降低骨质疏松性骨折的人口负担.
相关概念视频
Genetic Screens
5.6K
Genetic screens are tools used to identify genes and mutations responsible for phenotypes of interest. Genetic screens help identify individuals or a group of people at risk of developing genetic diseases and help them with early intervention, targeted therapy, and reproductive options.
Forward genetic screens
Forward or “classical” genetic screens involve creating random mutations in an organism’s DNA using radiation, mutagens, or insertion of additional bases, which...
Forward genetic screens
Forward or “classical” genetic screens involve creating random mutations in an organism’s DNA using radiation, mutagens, or insertion of additional bases, which...
5.6K
Imaging Studies for Cardiovascular System VI: Calcium -Scoring CT
384
Calcium-Scoring CT ScanA calcium-scoring CT scan, also known as coronary artery calcium (CAC) scan, detects calcium deposits in the coronary arteries. This test assesses the risk of coronary artery disease (CAD), which can lead to cardiovascular events such as angina, heart failure, and sudden cardiac arrest.A calcium-scoring CT scan is generally recommended for individuals at intermediate risk of CAD without symptoms. It includes:Men aged 40-75 and women aged 50-75: Especially those with a...
384
Bioavailability Study Design: Healthy Subjects Versus Patients
143
Bioavailability studies are essential for evaluating a drug's therapeutic efficacy and understanding its absorption patterns under various physiological conditions. Conducting such studies on target patient populations provides more relevant data by simulating real-world disease states. However, practical challenges often necessitate the use of young, healthy adult volunteers as study subjects.Patients may exhibit altered drug absorption patterns due to the effects of the disease itself,...
143
Analysis of Population Pharmacokinetic Data
673
Analysis of population pharmacokinetic data involves studying the behavior of drugs within diverse populations to understand their pharmacokinetic parameters. Traditional pharmacokinetic methods typically involve collecting samples from a few individuals and estimating these parameters. While these methods are commonly used, they have limitations in capturing the variability in drug response among individuals or heterogeneous populations. Population pharmacokinetics is employed to address these...
673
Drug Dosing: Obese Patients
218
In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
218

